BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37980167)

  • 1. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
    Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
    Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
    Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
    Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma.
    Zhang Z; Wu L; Li J; Chen J; Yu Q; Yao H; Xu Y; Liu L
    J Transl Med; 2022 Dec; 20(1):602. PubMed ID: 36522647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prognostic biomarker:
    Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
    Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
    Zhang C; Peng L; Gu H; Wang J; Wang Y; Xu Z
    Sci Rep; 2023 Jan; 13(1):1583. PubMed ID: 36709331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma.
    Han J; Wang Y; Zhou H; Ai S; Wan D
    Comput Math Methods Med; 2022; 2022():6267851. PubMed ID: 36238495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
    Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D
    J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
    Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
    Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
    He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
    Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma.
    Shi L; Shang X; Nie K; Lin Z; Zheng M; Wang M; Yuan H; Zhu Z
    J Clin Pathol; 2021 Aug; 74(8):504-512. PubMed ID: 33004423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.
    Lin YR; Yang WJ; Yang GW
    Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.
    Chen X; Yang M; Wang L; Wang Y; Tu J; Zhou X; Yuan X
    BMC Cancer; 2023 May; 23(1):411. PubMed ID: 37149620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.
    Pan Y; Zhu Q; Hong T; Cheng J; Tang X
    Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.